Finance

Lists
000739:SHE
Apeloa Pharmaceutical Co Ltd
CNÂ¥19.37
-0.67%
(-0.13) 1D
Oct 30, 3:04:03 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 000739...
Open
CNÂ¥19.23
High
CNÂ¥20.16
Low
CNÂ¥18.71
Mkt. cap
22.44B
Avg. vol.
17.57M
Volume
18.55M
Dividend
1.95%
Quarterly dividend
CNÂ¥0.09
Ex-dividend date
Oct 8, 2026
P/E ratio
27.81
52-wk high
CNÂ¥28.50
52-wk low
CNÂ¥14.92
EPS
CNÂ¥0.70
Shares outstanding
1.16B
No. of employees
7K
Open
CNÂ¥19.23
High
CNÂ¥20.16
Low
CNÂ¥18.71
Mkt. cap
22.44B
Avg. vol.
17.57M
Volume
18.55M
Dividend
1.95%
Quarterly dividend
CNÂ¥0.09
Ex-dividend date
Oct 8, 2026
P/E ratio
27.81
52-wk high
CNÂ¥28.50
52-wk low
CNÂ¥14.92
EPS
CNÂ¥0.70
Shares outstanding
1.16B
No. of employees
7K
News stories
From web sources and news partners
Profile
Apeloa Pharmaceutical Co., Ltd., known as Apeloa, is a Chinese pharmaceutical manufacturer under Hengdian Group. The company is headquartered in Hengdian, Dongyang, Zhejiang, China. It was founded in 1989 and has been listed on the Shenzhen Stock Exchange since 9 May 1997. Apeloa provides contract development and manufacturing services and manufactures APIs and finished dosage forms; products span cardiovascular, anti-infective, psychiatric and oncology areas. Apeloa has 7400 employees, 8 manufacturing sites and 3 R&D centers in Boston, Shanghai and Hengdian, covering flow chemistry, synthetic biology and biocatalysis, and peptide development. It has invested over USD20 million in flow chemistry over the past ten years in an effort to advance sustainable pharmaceutical manufacturing. In Boston, its 17,000-square-foot facility does R&D related to chemistry needs in drug development, including preclinical chemistry, scale-up production and new drug development. Apeloa Pharmaceutical has successfully passed 20 U.S. FDA inspections since 2006. Wikipedia
About Apeloa Pharmaceutical Co Ltd
CEO-
Employees6.79K
Founded1989
Headquarters-
SectorPharmaceutical industry
Websiteapeloa.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
2.02B
2.45B
2.38B
2.01B
Cost of goods sold
1.48B
1.73B
1.69B
1.52B
Cost of revenue
1.48B
1.73B
1.69B
1.52B
Research and development expenses
146.16M
134.93M
143.88M
148.40M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
275.50M
219.12M
203.71M
199.59M
Operating expense
483.17M
380.47M
371.82M
331.32M
Total operating expenses
1.96B
2.11B
2.06B
1.85B
Operating income
60.19M
336.71M
311.76M
158.37M
Other non operating income
7.46M
-33.21M
31.72M
-87.96M
EBT including unusual items
227.06M
297.81M
323.80M
116.01M
EBT excluding unusual items
80.73M
306.22M
288.49M
136.17M
Income tax expense
36.57M
48.54M
50.52M
26.00M
Effective tax rate
16.10%
16.30%
15.60%
22.41%
Other operating expenses
53.54M
13.18M
11.46M
-10.43M
Net income
190.41M
249.02M
273.35M
91.29M
Net profit margin
9.43%
10.17%
11.51%
4.54%
Earnings per share
-
-
-
-
Interest and investment income
46.65M
10.66M
17.28M
9.17M
Interest expense
-8.06M
-7.95M
-8.10M
-7.59M
Net interest expenses
38.60M
2.71M
9.18M
1.58M
Depreciation and amortization charges
-
-
-
-
EBITDA
225.73M
502.26M
478.57M
323.92M
Gain or loss from assets sale
-9.03M
-
-136.29K
136.29K
Upcoming events
AI content may include mistakes. Learn more
Google apps